The study will contribute a replicable model for improving risk prediction from patient characteristics, clinical severity indicators, and genomic tests to aid in personalizing treatment. The proposed registry would also allow future comparisons of the gene expression used in other competing commercial test. The addition of the suggested genomic classifier and its associations with other patient and clinical characteristics will enhance the ability of future studies, analogous to CEASAR, to accurately predict the risk of tumor aggressiveness in prostate cancer.
Age
18–90
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
18 - 90 years of age
Prostate-Specific Antigen (PSA) values \<50ng/ml
Clinical stage of T1 or T2
No evidence of metastasis or nodal involvement
You may not be if
Age 91 or greater
Clinically locally advanced or metastatic disease
PSA equal to or greater than 50ng/ml
Diagnosis of malignancy (excluding squamous or basal cell carcinoma of the skin) within 3 years of diagnosis of prostate cancer